Navigation Links
Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
Date:10/23/2008

ess of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Dendreon Reports First Quarter 2008 Financial Results
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Announces Closing of Registered Direct Offering
7. Dendreon Announces $47 Million Registered Direct Offering
8. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
9. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
10. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... The Mexico Biomedical Sensors market is estimated at $0.20 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:8/31/2015)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... innovative therapies primarily in the areas of dermatology ... period following the filing of the Company,s Investigational ... U.S. Food and Drug Administration (FDA) has passed ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... Trimb Healthcare AB ("Trimb") today announced that it has ... a Dutch OTC company with operations in key European ... 16 million, with solid growth and leading brands in ... build a leading international OTC company, and this acquisition ... us a stronger North European OTC platform, from which ...
(Date:8/30/2015)... England , August 31, 2015 ...   einer Frau   für chirurgische   Behandlung     ... von 7-90   werden für eine   verheerende ... 1200 Frauen behandeln und die Anzahl ausgebildeter Chirurgen in ... Astellas gab heute bekannt, dass  Action on Fistula ...
Breaking Biology Technology:Mexico Biomedical Sensors Market Report 2015-2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
... MannKind Corporation (Nasdaq: MNKD ) today ... Inc. (NYSE: PFE ) to purchase Pfizer,s ... and assets related to the production of bulk insulin, ... a quantity of bulk insulin and a license to ...
... computational resources the idea of a computational laboratory ... conceptual and technical challenges. Chief among these is ... of incomplete knowledge and information, reflected in observed ... has, in recent years, grown from a collection ...
... a leading medical device/biopharmaceutical company located in Santa Ana, ... CHO-CD XP(TM) Culture System to their cell culture product ... set of chemically-defined*, serum-free, and animal component free media ... and production for recombinant CHO cell lines. It ...
Cached Biology Technology:MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 2MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 3MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 4Opportunities and challenges in uncertainty quantification for complex interacting systems 2Irvine Scientific Launches IS CHO-CD XP(TM) 2
(Date:8/12/2015)... CORAL SPRINGS, Florida , August 12, 2015 /PRNewswire/ ... globally, the pace of mobile payment innovation and advanced ... continues to replace the way consumers rely on using ... forges ahead with reinventing the future for payment services ... Inc. (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... a big killer, responsible for more than 35,000 deaths in ... with the deadly H5N1 strain of bird flu are gradually ... scientists are discussing ways to better understand the flu and ... modify flu as a bioweapon to make it even more ...
... Cigarette smoke can turn normal breast cells cancerous by ... development, University of Florida scientists report. , While some ... damaged DNA, many others become unable to access their ... a UF study published today (Aug. 21) in the ...
... here reveals that a new strain of mice offers the ... leukemia and should greatly aid the development of new drugs ... transgenic mouse, develops a malignancy that closely mimics chronic lymphocytic ... hampered the development of new treatments for CLL as well ...
Cached Biology News:Scientists aim to thwart use of flu as bioweapon 2Scientists aim to thwart use of flu as bioweapon 3Cigarette smoke blocks cell repair mechanism, University of Florida study shows 2Cigarette smoke blocks cell repair mechanism, University of Florida study shows 3Mouse mimics chronic leukemia, will aid drug development 2
... Timp-4 has been reported in heart ... fibroblasts in cell culture conditions. ... TPA stimulates production of TIMP-4 in ... protein levels produced often require concentration ...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
...
Biology Products: